Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 981 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methotrexate Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Fullerton, California • Los Alamitos, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3871801 in Healthy Participants

NCT05602675
View directory record Official record
Conditions
Healthy
Interventions
LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 24, 2026, 1:06 AM EDT
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ASP5094, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

NCT04762498
View directory record Official record
Conditions
Uncontrolled Gout, Chronic Gout
Interventions
Pegloticase, Methotrexate (MTX)
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

NCT01012492
View directory record Official record
Conditions
AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts), Myelodysplastic Syndrome, Unclassified, MDS Associated With Isolated Del (5q)
Interventions
Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

NCT00023998
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 24, 2026, 1:06 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Stem Cell Transplant for CLL

NCT01629511
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Richter Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Filgrastim, Gemcitabine, Methotrexate, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 24, 2026, 1:06 AM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 24, 2026, 1:06 AM EDT
Completed No phase listed Observational

Prediction of Methotrexate Response - A Pilot Study

NCT01726959
View directory record Official record
Conditions
Rheumatoid Arthritis, Rheumatic Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

NCT02405780
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
FKB327, Humira®
Drug
Lead sponsor
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Peoria, Arizona • Palm Desert, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 24, 2026, 1:06 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT00940524
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

NCT01664910
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine Hydrochloride, Fludarabine Phosphate, Inotuzumab Ozogamicin, Methotrexate, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 1 Interventional Results available

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

NCT00742924
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 4 Interventional Results available

Rheumatoid Arthritis Memory B Cells and Abatacept

NCT03652961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, DMARDs
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 24, 2026, 1:06 AM EDT
Completed No phase listed Observational

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

NCT00437060
View directory record Official record
Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Cognitive Side Effects of Cancer Therapy, Long-Term Effects Secondary to Cancer Therapy in Children, Neurotoxicity Syndrome, Psychological Impact of Cancer, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
Cognitive Assessment, Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Pharmacological Study, Psychosocial Assessment and Care
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Downey, California • Long Beach, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 24, 2026, 1:06 AM EDT
Withdrawn Phase 1 Interventional

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

NCT00957320
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Sirolimus, PEG-asparaginase
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 24, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

NCT00001677
View directory record Official record
Conditions
Arthritis, Rheumatoid, Synovitis
Interventions
Methotrexate, Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 1:06 AM EDT